Cosmos Health announces Q3 adjusted earnings per share of 2 cents, compared to a loss of 34 cents in the previous year.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 17 2025
0mins
Should l Buy COSM?
Q3 Financial Performance: Cosmos Health reported a Q3 revenue of $17.11 million, up from $12.41 million the previous year, marking a significant increase in financial performance.
Strategic Financing: The company secured a $300 million financing facility aimed at building a digital assets portfolio and enhancing core operations, which is expected to support long-term growth.
Business Growth: Key subsidiaries, including Cana Laboratories and Decahedron, achieved record results, while the CosmoFarm distribution business expanded its network and volume, indicating strong operational momentum.
Future Outlook: Cosmos Health is focused on disciplined growth and margin expansion, with an optimistic trajectory heading into Q4 2025, driven by advancements in R&D and international expansion of its nutraceutical brand.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COSM
About COSM
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cosmos Health Appoints AI Drug Development Expert to Advisory Board
- Expert Appointment: Cosmos Health has appointed Dr. Dimitrios Iliopoulos to its Advisory Board, whose expertise in AI-driven drug discovery and clinical development will significantly enhance the company's biotechnology platform and drive strategic growth in high-value therapeutic areas.
- Innovative Platform: Dr. Iliopoulos is the co-founder of Athos Therapeutics, which developed the AthosOmics.AI platform that successfully discovered ATH-063, a small molecule currently in Phase 2 clinical trials for autoimmune diseases, thereby enhancing Cosmos Health's R&D capabilities.
- Academic Background: With a distinguished academic career at Harvard Medical School and UCLA, Dr. Iliopoulos has received multiple national and international awards and has published over 130 peer-reviewed articles with more than 24,000 citations, underscoring his influence in drug development.
- Strategic Vision: CEO Greg Siokas stated that Dr. Iliopoulos's addition will provide crucial support for the company's R&D in oncology and autoimmune diseases, aiding Cosmos Health's expansion and innovation in the global healthcare market.
See More
Cosmos Health Evaluates Real Estate Asset Value
- Real Estate Valuation: Cosmos Health estimates the combined fair market value of its Cana Laboratories and CosmoFarm logistics center at approximately $15 million, reflecting favorable macro conditions in the Greek property market and indicating that the intrinsic value of its assets exceeds its current market capitalization of $13.5 million.
- Strategic Monetization Options: The company is considering various strategic monetization avenues, including outright sales, joint ventures, or sale-leaseback transactions, which, if executed successfully, could yield proceeds comparable to or exceeding its current market cap, thereby enhancing financial flexibility.
- Geographical Advantage: The Cana facility, located in Neo Iraklio, Athens, spans 54,000 square feet of land and 35,700 square feet of built space, strategically positioned for future development and alternative uses, supporting the company's long-term growth in the pharmaceutical sector.
- Enhanced Financial Transparency: CEO Greg Siokas highlighted the significant disconnect between the company's current valuation and the intrinsic value of its assets, emphasizing that a well-executed monetization strategy could create substantial value for shareholders and strengthen its position in the global healthcare market.
See More
Cosmos Health Expands Retail Footprint in the UK
- Market Expansion: Cosmos Health's antimicrobial skin cleanser, C-Scrub, is now available at Superdrug, the UK's second-largest beauty and health retailer, marking a significant expansion in the UK market that is expected to enhance brand visibility and market share.
- Retail Network Advantage: With over 830 stores across the UK and Ireland, including more than 200 pharmacies, Superdrug's listing of C-Scrub will significantly enhance its influence in the health and personal care sectors, further solidifying Cosmos Health's market position.
- Product Features: C-Scrub is a powerful antiseptic wash designed to reduce bacteria and help prevent infections, supporting effective skin hygiene and aligning with the growing consumer demand for health-focused products.
- Strategic Significance: CEO Greg Siokas stated that entering Superdrug reinforces the retail momentum for C-Scrub in the UK, strengthening the company's market positioning across diverse retail platforms and supporting the long-term development of its broader product portfolio.
See More
Cosmos Health Expands UK Retail Footprint with Tesco Partnership
- Retail Channel Expansion: Cosmos Health's antimicrobial skin cleanser, C-Scrub, is now available at Tesco, the UK's largest retailer with over $80 billion in annual revenue and nearly 30% market share, significantly enhancing C-Scrub's visibility and accessibility.
- Market Leadership: The partnership with Tesco not only boosts Cosmos Health's credibility in the UK market but also establishes a solid foundation for the potential rollout of additional products, further solidifying its position in European markets.
- Product Advantages: C-Scrub, designed to reduce bacteria and help prevent infection, supports effective skin hygiene and is expected to meet the growing demand for efficient cleaning products among UK consumers.
- Strategic Growth Opportunity: CEO Greg Siokas stated that this collaboration with Tesco represents a pivotal moment for Cosmos Health, providing not only growth opportunities for C-Scrub but also a powerful platform for future product launches, demonstrating the company's commitment to global market expansion.
See More
Cosmos Health Showcases at World Health Expo Dubai 2026
- Expo Participation: Cosmos Health participated in the World Health Expo Dubai from February 9-12, 2026, attracting over 235,000 visitors and 4,300 exhibitors, showcasing its influence in the global healthcare sector.
- Brand Promotion: The company highlighted its flagship product, Sky Premium Life®, which has strengthened its presence in Europe and the Middle East through expanded distribution agreements and new product launches, expected to drive future sales growth.
- Strategic Partnerships: During the expo, CEO Greg Siokas held productive meetings with potential commercial partners from new regions including Japan, China, and Latin America, aiming to strengthen strategic relationships and advance several potential agreements.
- Global Expansion: Cosmos Health successfully entered the North American market through its U.S. manufacturing capabilities and plans to further expand its global distribution network to support long-term brand development and value creation.
See More
Cosmos Health Expands Digital Asset Investment Strategy
- Digital Asset Expansion: Cosmos Health Inc. announced a $500,000 purchase of Bitcoin, marking an expansion of its digital assets program aimed at enhancing flexibility and diversification in capital deployment.
- Strategic Evolution: While Ethereum remains a cornerstone of the program, the addition of Bitcoin reflects the company's adaptability to market dynamics, expected to enhance its competitiveness in the digital asset space.
- Total Investment: To date, Cosmos Health has invested a total of $2.5 million in cryptocurrencies, demonstrating its ongoing commitment and strategic positioning in the digital asset arena.
- CEO Insights: CEO Greg Siokas stated that the investment in Bitcoin, executed at an average price below $70,000, reflects the potential for value creation by deploying capital during market downturns, further solidifying its overall capital deployment strategy.
See More
Cosmos Health Appoints AI Drug Development Expert to Advisory Board
- Expert Appointment: Cosmos Health has appointed Dr. Dimitrios Iliopoulos to its Advisory Board, whose expertise in AI-driven drug discovery and clinical development will significantly enhance the company's biotechnology platform and drive strategic growth in high-value therapeutic areas.
- Innovative Platform: Dr. Iliopoulos is the co-founder of Athos Therapeutics, which developed the AthosOmics.AI platform that successfully discovered ATH-063, a small molecule currently in Phase 2 clinical trials for autoimmune diseases, thereby enhancing Cosmos Health's R&D capabilities.
- Academic Background: With a distinguished academic career at Harvard Medical School and UCLA, Dr. Iliopoulos has received multiple national and international awards and has published over 130 peer-reviewed articles with more than 24,000 citations, underscoring his influence in drug development.
- Strategic Vision: CEO Greg Siokas stated that Dr. Iliopoulos's addition will provide crucial support for the company's R&D in oncology and autoimmune diseases, aiding Cosmos Health's expansion and innovation in the global healthcare market.
See More
Cosmos Health Evaluates Real Estate Asset Value
- Real Estate Valuation: Cosmos Health estimates the combined fair market value of its Cana Laboratories and CosmoFarm logistics center at approximately $15 million, reflecting favorable macro conditions in the Greek property market and indicating that the intrinsic value of its assets exceeds its current market capitalization of $13.5 million.
- Strategic Monetization Options: The company is considering various strategic monetization avenues, including outright sales, joint ventures, or sale-leaseback transactions, which, if executed successfully, could yield proceeds comparable to or exceeding its current market cap, thereby enhancing financial flexibility.
- Geographical Advantage: The Cana facility, located in Neo Iraklio, Athens, spans 54,000 square feet of land and 35,700 square feet of built space, strategically positioned for future development and alternative uses, supporting the company's long-term growth in the pharmaceutical sector.
- Enhanced Financial Transparency: CEO Greg Siokas highlighted the significant disconnect between the company's current valuation and the intrinsic value of its assets, emphasizing that a well-executed monetization strategy could create substantial value for shareholders and strengthen its position in the global healthcare market.
See More
Cosmos Health Expands Retail Footprint in the UK
- Market Expansion: Cosmos Health's antimicrobial skin cleanser, C-Scrub, is now available at Superdrug, the UK's second-largest beauty and health retailer, marking a significant expansion in the UK market that is expected to enhance brand visibility and market share.
- Retail Network Advantage: With over 830 stores across the UK and Ireland, including more than 200 pharmacies, Superdrug's listing of C-Scrub will significantly enhance its influence in the health and personal care sectors, further solidifying Cosmos Health's market position.
- Product Features: C-Scrub is a powerful antiseptic wash designed to reduce bacteria and help prevent infections, supporting effective skin hygiene and aligning with the growing consumer demand for health-focused products.
- Strategic Significance: CEO Greg Siokas stated that entering Superdrug reinforces the retail momentum for C-Scrub in the UK, strengthening the company's market positioning across diverse retail platforms and supporting the long-term development of its broader product portfolio.
See More
Cosmos Health Expands UK Retail Footprint with Tesco Partnership
- Retail Channel Expansion: Cosmos Health's antimicrobial skin cleanser, C-Scrub, is now available at Tesco, the UK's largest retailer with over $80 billion in annual revenue and nearly 30% market share, significantly enhancing C-Scrub's visibility and accessibility.
- Market Leadership: The partnership with Tesco not only boosts Cosmos Health's credibility in the UK market but also establishes a solid foundation for the potential rollout of additional products, further solidifying its position in European markets.
- Product Advantages: C-Scrub, designed to reduce bacteria and help prevent infection, supports effective skin hygiene and is expected to meet the growing demand for efficient cleaning products among UK consumers.
- Strategic Growth Opportunity: CEO Greg Siokas stated that this collaboration with Tesco represents a pivotal moment for Cosmos Health, providing not only growth opportunities for C-Scrub but also a powerful platform for future product launches, demonstrating the company's commitment to global market expansion.
See More
Cosmos Health Showcases at World Health Expo Dubai 2026
- Expo Participation: Cosmos Health participated in the World Health Expo Dubai from February 9-12, 2026, attracting over 235,000 visitors and 4,300 exhibitors, showcasing its influence in the global healthcare sector.
- Brand Promotion: The company highlighted its flagship product, Sky Premium Life®, which has strengthened its presence in Europe and the Middle East through expanded distribution agreements and new product launches, expected to drive future sales growth.
- Strategic Partnerships: During the expo, CEO Greg Siokas held productive meetings with potential commercial partners from new regions including Japan, China, and Latin America, aiming to strengthen strategic relationships and advance several potential agreements.
- Global Expansion: Cosmos Health successfully entered the North American market through its U.S. manufacturing capabilities and plans to further expand its global distribution network to support long-term brand development and value creation.
See More
Cosmos Health Expands Digital Asset Investment Strategy
- Digital Asset Expansion: Cosmos Health Inc. announced a $500,000 purchase of Bitcoin, marking an expansion of its digital assets program aimed at enhancing flexibility and diversification in capital deployment.
- Strategic Evolution: While Ethereum remains a cornerstone of the program, the addition of Bitcoin reflects the company's adaptability to market dynamics, expected to enhance its competitiveness in the digital asset space.
- Total Investment: To date, Cosmos Health has invested a total of $2.5 million in cryptocurrencies, demonstrating its ongoing commitment and strategic positioning in the digital asset arena.
- CEO Insights: CEO Greg Siokas stated that the investment in Bitcoin, executed at an average price below $70,000, reflects the potential for value creation by deploying capital during market downturns, further solidifying its overall capital deployment strategy.
See More
